Market atlas / Mitochondrial / Alpha-lipoic acid

Alpha-lipoic acid (mitochondrial antioxidant)

traditional-to-validatedsmall-moleculemitochondrial-cofactorantioxidant

Stage by geography

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKKRCN+3 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	consumer	not dated	not published
UK	RCT	1998-05-01	not published
CN	signal	2013-11-01	not published
KR	RCT	not dated	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on Alpha-lipoic acid, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Primary efficacy variable: Absolute change in the neuropathy impairment score lower limbs enlarged by 7 objective items (NISLL+7)…	UK, US
Change From Baseline in Activities of Daily Living (ADL) at 18 Months	US
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months	US
Intracellular advanced glycation endproducts	US
Hexosamine pathway	US
Prostacyclin synthase activity	US
Paced Auditory Serial Addition Task (PASAT)	US
Stroop Color-Word Test	US
California Verbal Learning Test-II (CVLT-II)	US
Controlled Oral Word Association Test (COWAT)	US

Connections

Trajectory

1998

MarketUK: rct (clinical trials (highest phase 3))

NCT00977483 · machine-extracted

2003

Relatedshares a mechanism with Coq10

NCT00079807 · machine-extracted

2003

ProfileAlpha-lipoic acid (mitochondrial antioxidant)

NCT00079807 · machine-extracted

2003

MarketUS: rct (clinical trials (highest phase 2))

NCT00079807 · machine-extracted

2013

MarketCN: signal (early clinical signal (single trial))

NCT01877590 · machine-extracted

2026

MarketUS: consumer (US dietary supplement (DSHEA), not FDA-approved as a drug)

DSLD:310640 · machine-extracted

2026

MarketKR: rct (clinical trials (highest phase 2))

NCT01396733 · machine-extracted

Get into the weeds: raw observations + provenance

ala_uk  2026-06-29  kind=geography_stage  verify=M
   Alpha-lipoic acid: a UK phase 3 trial [NCT00977483]
   source NCT00977483  https://clinicaltrials.gov/study/NCT00977483

ala_edge_coq  2026-06-29  kind=edge  verify=M
   both mitochondrial-support antioxidants
   source NCT00079807  https://clinicaltrials.gov/study/NCT00079807

ala_facets  2026-06-29  kind=facets  verify=M
   Alpha-lipoic acid facets
   source NCT00079807  https://clinicaltrials.gov/study/NCT00079807

ala_us_trial  2026-06-29  kind=geography_stage  verify=M
   Alpha-lipoic acid: US phase 2 trials [NCT00079807]
   source NCT00079807  https://clinicaltrials.gov/study/NCT00079807

ala_cn  2026-06-29  kind=geography_stage  verify=M
   Alpha-lipoic acid: a single registered trial in China [NCT01877590]
   source NCT01877590  https://clinicaltrials.gov/study/NCT01877590

ala_us_consumer  2026-06-29  kind=geography_stage  verify=M
   Alpha-lipoic acid sold as a US dietary supplement
   source DSLD:310640  https://dsld.od.nih.gov/label/310640

ctsearch__KR__dev_ala  2026-07-10  kind=geography_stage  verify=M
   alpha-lipoic acid: 4 registered trial(s) in KR, highest phase 2 [NCT01396733]
   source NCT01396733  https://clinicaltrials.gov/study/NCT01396733